Gene Test for Rapid Sepsis Diagnosis
Sepsis is a syndrome caused by infection which can lead to organ failure. Four of the top 10 causes of death worldwide involve infection and meet the definition of sepsis. Each year, some 18 million cases of sepsis are reported across the world.
The UBC researchers identified a "gene signature" that is related with the eventual diagnosis of sepsis and subsequent organ failure. "We can test for this genetic signature as soon as the patient arrives in the emergency ward," said Bob Hancock, a professor in UBC's Department of Microbiology and Immunology who co-authored the study with John Boyd, a physician at St. Paul's Hospital (Vancouver) and an assistant professor at UBC.
The new test, the researchers said, could cut back on the lengthy diagnostic time usually required to confirm if a patient is suffering from sepsis and increase the odds that they will respond to treatment. The new test for the genetic signature would take as little as one hour and was able to identify 96 percent of patients who were at the very early stages of sepsis, the study authors noted.
"With sepsis, every hour counts," Hancock emphasised. "The treatment involves aggressive antibiotics but the most potent drugs can't be administered until a diagnosis is confirmed because of the risk of antibiotic resistant bacteria."
Results of the UBC study have also revealed a potential misunderstanding about the disease. To date, sepsis has been treated as an inflammatory disease but more than 30 clinical trials of anti-inflammatory drugs for sepsis have failed. The gene signature identified by Hancock et al. relates to a special type of immune suppression called cellular reprogramming and suggests that treating inflammation in sepsis is a bad idea.
PCSK9 Enzyme May be Key to Stopping Fatal Sepsis Outcomes
Meanwhile, another UBC-led study has discovered that controlling levels of the human enzyme PCSK9 could mean the difference between life and death for patients with severe sepsis. The study has been published in the journal Science Translation Medicine.
According to UBC researcher Keith Walley, inhibiting or reducing PCSK9 could allow the patient’s body to clear toxic remnants of bacteria and fungi destroyed by antibiotics. Eliminating the infection’s waste may improve the patient’s outcomes and survival rates.
Treatment of mice with severe sepsis using a PCSK9 inhibitor increased survival. Mice with a genetic variation that reduced the levels of PCSK9 also showed improved sepsis outcomes and survival rates, said the research team.
Currently, many drug companies are developing PCSK9 inhibitors to increase clearance of cholesterol thereby lowering cardiovascular risk. This raises the possibility that a PCSK9 inhibitor treatment is possible and treatment of sepsis in humans with a PCSK9 inhibitor might increase survival.
Image Credit: BBC News
Published on : Fri, 24 Oct 2014
ExThera’s proprietary Seraph 100 Microbind Affinity Blood Filter (Seraph 100) is a first-of-its kind, CE Marked, technology designed to reduce bloodborne pathogens during bloodstream infections. Validated in preclinical studies and in a clinical trial...
Intended for uncomplicated, atraumatic endotracheal tube exchange. Features and benefits The blunt, soft, and flexible tip of the catheter is atraumatic to internal structures. The distal section of the catheter is flexible. The extra-firm...
The system is easy to use and delivers incredibly fast, accurate, and standardized results with minimal centrifugation time of five minutes. Beyond Results. Confidence. Leverage the comprehensive power of Ortho’s trusted testing menu....
Not yet available in the U.S. The most extensively studied and proven glucose measurement technology In addition to studies submitted to the FDA, 168 other independent studies over the last eight years—including 53 critical care studies—have...
NovaPort cannulas are designed specially to meet the needs of extracorporeal heart and lung support circuits and perioperative perfusion in minimally invasive heart surgery. All blood-contact surfaces of the NovaPort cannulas are coated with the bio-...